An evaluation of emerging vaccines for childhood pneumococcal pneumonia

Julia Webster; Evropi Theodoratou; Harish Nair; Ang Choon Seong; Lina Zgaga; Tanvir Huda; Hope L Johnson; Shabir Madhi; Craig Rubens; Jian Shayne F Zhang; Shams El Arifeen; Ryoko Krause; Troy A Jacobs; Abdullah W Brooks; Harry Campbell; Igor Rudan

doi:10.1186/1471-2458-11-S3-S26

An evaluation of emerging vaccines for childhood pneumococcal pneumonia

Julia Webster, Evropi Theodoratou, Harish Nair, Ang Choon Seong, Lina Zgaga, Tanvir Huda, Hope L Johnson, Shabir Madhi, Craig Rubens, Jian Shayne F Zhang, Shams El Arifeen, Ryoko Krause, Troy A Jacobs, Abdullah W Brooks, Harry Campbell, Igor Rudan

Deanery of Clinical Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

Pneumonia is the leading cause of child mortality worldwide. Streptococcus pneumoniae (SP) or pneumococcus is estimated to cause 821,000 child deaths each year. It has over 90 serotypes, of which 7 to 13 serotypes are included in current formulations of pneumococcal conjugate vaccines that are efficacious in young children. To further reduce the burden from SP pneumonia, a vaccine is required that could protect children from a greater diversity of serotypes. Two different types of vaccines against pneumococcal pneumonia are currently at varying stages of development: a multivalent pneumococcal conjugate vaccine covering additional SP serotypes; and a conserved common pneumococcal protein antigen (PPA) vaccine offering protection for all serotypes.

Original language	English
Pages (from-to)	S26
Journal	BMC Public Health
Volume	11 Suppl 3
DOIs	https://doi.org/10.1186/1471-2458-11-S3-S26
Publication status	Published - 2011

Access to Document

10.1186/1471-2458-11-S3-S26

An evaluation of emerging vaccines for childhood pneumococcal pneumonia
© 2011 Webster et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Final published version, 413 KB

http://www.biomedcentral.com/1471-2458/11/S3/S26

Fingerprint Dive into the research topics of 'An evaluation of emerging vaccines for childhood pneumococcal pneumonia'. Together they form a unique fingerprint.

Cite this

Webster, J., Theodoratou, E., Nair, H., Seong, A. C., Zgaga, L., Huda, T., Johnson, H. L., Madhi, S., Rubens, C., Zhang, J. S. F., El Arifeen, S., Krause, R., Jacobs, T. A., Brooks, A. W., Campbell, H., & Rudan, I. (2011). An evaluation of emerging vaccines for childhood pneumococcal pneumonia. BMC Public Health, 11 Suppl 3, S26. https://doi.org/10.1186/1471-2458-11-S3-S26

Webster, Julia ; Theodoratou, Evropi ; Nair, Harish ; Seong, Ang Choon ; Zgaga, Lina ; Huda, Tanvir ; Johnson, Hope L ; Madhi, Shabir ; Rubens, Craig ; Zhang, Jian Shayne F ; El Arifeen, Shams ; Krause, Ryoko ; Jacobs, Troy A ; Brooks, Abdullah W ; Campbell, Harry ; Rudan, Igor. / An evaluation of emerging vaccines for childhood pneumococcal pneumonia. In: BMC Public Health. 2011 ; Vol. 11 Suppl 3. pp. S26.

@article{ed590ed0f1074a90af83f55ab4ee3c4d,

title = "An evaluation of emerging vaccines for childhood pneumococcal pneumonia",

abstract = "Pneumonia is the leading cause of child mortality worldwide. Streptococcus pneumoniae (SP) or pneumococcus is estimated to cause 821,000 child deaths each year. It has over 90 serotypes, of which 7 to 13 serotypes are included in current formulations of pneumococcal conjugate vaccines that are efficacious in young children. To further reduce the burden from SP pneumonia, a vaccine is required that could protect children from a greater diversity of serotypes. Two different types of vaccines against pneumococcal pneumonia are currently at varying stages of development: a multivalent pneumococcal conjugate vaccine covering additional SP serotypes; and a conserved common pneumococcal protein antigen (PPA) vaccine offering protection for all serotypes.",

author = "Julia Webster and Evropi Theodoratou and Harish Nair and Seong, {Ang Choon} and Lina Zgaga and Tanvir Huda and Johnson, {Hope L} and Shabir Madhi and Craig Rubens and Zhang, {Jian Shayne F} and {El Arifeen}, Shams and Ryoko Krause and Jacobs, {Troy A} and Brooks, {Abdullah W} and Harry Campbell and Igor Rudan",

year = "2011",

doi = "10.1186/1471-2458-11-S3-S26",

language = "English",

volume = "11 Suppl 3",

pages = "S26",

journal = "BMC Public Health",

issn = "1471-2458",

publisher = "BioMed Central",

}

An evaluation of emerging vaccines for childhood pneumococcal pneumonia. / Webster, Julia; Theodoratou, Evropi ; Nair, Harish; Seong, Ang Choon; Zgaga, Lina; Huda, Tanvir; Johnson, Hope L; Madhi, Shabir; Rubens, Craig; Zhang, Jian Shayne F; El Arifeen, Shams; Krause, Ryoko; Jacobs, Troy A; Brooks, Abdullah W; Campbell, Harry ; Rudan, Igor.

In: BMC Public Health, Vol. 11 Suppl 3, 2011, p. S26.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - An evaluation of emerging vaccines for childhood pneumococcal pneumonia

AU - Webster, Julia

AU - Theodoratou, Evropi

AU - Nair, Harish

AU - Seong, Ang Choon

AU - Zgaga, Lina

AU - Huda, Tanvir

AU - Johnson, Hope L

AU - Madhi, Shabir

AU - Rubens, Craig

AU - Zhang, Jian Shayne F

AU - El Arifeen, Shams

AU - Krause, Ryoko

AU - Jacobs, Troy A

AU - Brooks, Abdullah W

AU - Campbell, Harry

AU - Rudan, Igor

PY - 2011

Y1 - 2011

N2 - Pneumonia is the leading cause of child mortality worldwide. Streptococcus pneumoniae (SP) or pneumococcus is estimated to cause 821,000 child deaths each year. It has over 90 serotypes, of which 7 to 13 serotypes are included in current formulations of pneumococcal conjugate vaccines that are efficacious in young children. To further reduce the burden from SP pneumonia, a vaccine is required that could protect children from a greater diversity of serotypes. Two different types of vaccines against pneumococcal pneumonia are currently at varying stages of development: a multivalent pneumococcal conjugate vaccine covering additional SP serotypes; and a conserved common pneumococcal protein antigen (PPA) vaccine offering protection for all serotypes.

AB - Pneumonia is the leading cause of child mortality worldwide. Streptococcus pneumoniae (SP) or pneumococcus is estimated to cause 821,000 child deaths each year. It has over 90 serotypes, of which 7 to 13 serotypes are included in current formulations of pneumococcal conjugate vaccines that are efficacious in young children. To further reduce the burden from SP pneumonia, a vaccine is required that could protect children from a greater diversity of serotypes. Two different types of vaccines against pneumococcal pneumonia are currently at varying stages of development: a multivalent pneumococcal conjugate vaccine covering additional SP serotypes; and a conserved common pneumococcal protein antigen (PPA) vaccine offering protection for all serotypes.

U2 - 10.1186/1471-2458-11-S3-S26

DO - 10.1186/1471-2458-11-S3-S26

M3 - Article

C2 - 21501444

VL - 11 Suppl 3

SP - S26

JO - BMC Public Health

JF - BMC Public Health

SN - 1471-2458

ER -